AR002261A1 - Composicion en polvo para la administracion por inhalacion de polipeptidos utiles en medicina, metodos para la manufactura de dicha composicion, y uso de la composicion para la manufactura de un medicamento para el tratamietno de enfermedades a traves del tracto respiratorio - Google Patents

Composicion en polvo para la administracion por inhalacion de polipeptidos utiles en medicina, metodos para la manufactura de dicha composicion, y uso de la composicion para la manufactura de un medicamento para el tratamietno de enfermedades a traves del tracto respiratorio

Info

Publication number
AR002261A1
AR002261A1 ARP950100706A AR10070695A AR002261A1 AR 002261 A1 AR002261 A1 AR 002261A1 AR P950100706 A ARP950100706 A AR P950100706A AR 10070695 A AR10070695 A AR 10070695A AR 002261 A1 AR002261 A1 AR 002261A1
Authority
AR
Argentina
Prior art keywords
composition
manufacture
tract
diseases
administration
Prior art date
Application number
ARP950100706A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR002261A1 publication Critical patent/AR002261A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Abstract

Una composición en polvo para la administración de polipéptidos medicinalmente útiles, que comprende un polipéptido medicinalmente conmelezitosa como diluyente. Además, se dan a conocer métodos para la manufactura de dicha composición en polvo parael tratamiento de enfermedades a través deltracto respiratorio.
ARP950100706A 1994-12-22 1995-12-21 Composicion en polvo para la administracion por inhalacion de polipeptidos utiles en medicina, metodos para la manufactura de dicha composicion, y uso de la composicion para la manufactura de un medicamento para el tratamietno de enfermedades a traves del tracto respiratorio AR002261A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9404468A SE9404468D0 (sv) 1994-12-22 1994-12-22 Powder formulations

Publications (1)

Publication Number Publication Date
AR002261A1 true AR002261A1 (es) 1998-03-11

Family

ID=20396435

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100706A AR002261A1 (es) 1994-12-22 1995-12-21 Composicion en polvo para la administracion por inhalacion de polipeptidos utiles en medicina, metodos para la manufactura de dicha composicion, y uso de la composicion para la manufactura de un medicamento para el tratamietno de enfermedades a traves del tracto respiratorio

Country Status (34)

Country Link
US (1) US6004574A (es)
EP (2) EP0799030B1 (es)
JP (1) JPH10510828A (es)
KR (1) KR100391873B1 (es)
CN (1) CN1080114C (es)
AR (1) AR002261A1 (es)
AT (2) ATE271382T1 (es)
AU (1) AU702898B2 (es)
BR (1) BR9510422A (es)
CA (1) CA2206803A1 (es)
CZ (1) CZ288487B6 (es)
DE (2) DE69533294T2 (es)
DK (2) DK0799030T3 (es)
EE (1) EE03381B1 (es)
ES (2) ES2177674T3 (es)
FI (1) FI972654A0 (es)
HK (1) HK1003619A1 (es)
HU (1) HU217975B (es)
IL (1) IL116459A (es)
IS (1) IS1848B (es)
MY (1) MY114211A (es)
NO (1) NO315966B1 (es)
NZ (1) NZ298168A (es)
PL (1) PL183944B1 (es)
PT (2) PT1224929E (es)
RU (1) RU2144819C1 (es)
SA (1) SA95160484B1 (es)
SE (1) SE9404468D0 (es)
SK (1) SK283147B6 (es)
TR (1) TR199501632A1 (es)
TW (1) TW474823B (es)
UA (1) UA44757C2 (es)
WO (1) WO1996019207A1 (es)
ZA (1) ZA9510753B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
NZ298169A (en) * 1994-12-22 1999-09-29 Astra Ab Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO1998042368A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
EP1169053A1 (en) 1999-04-13 2002-01-09 Inhale Therapeutic Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
EP1309312A2 (en) * 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
AU2002366267B2 (en) 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
CA2580313C (en) 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
CN101618023B (zh) * 2008-06-30 2011-11-30 江苏先声药物研究有限公司 一种制备微粉化蛋白的方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
DK2561070T3 (en) 2010-04-20 2015-08-17 Octapharma Ag NEW STABILIZER FOR PHARMACEUTICAL PROTEINS
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
US9480966B2 (en) * 2012-04-30 2016-11-01 General Electric Company Substrates and methods for collection, stabilization and elution of biomolecules
JP6533777B2 (ja) * 2014-03-25 2019-06-19 国立大学法人 香川大学 希少糖を有効成分とするマラリア伝播阻止剤およびマラリア原虫の発育阻害剤
CA2953574A1 (en) * 2014-06-30 2016-01-07 Tate & Lyle Ingredients Americas Llc Coating compositions for consumable articles
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
ES2818569T3 (es) 2015-09-09 2021-04-13 Drawbridge Health Inc Métodos para la recopilación, estabilización y conservación de muestras
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (es) * 1957-01-31 1957-04-11
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE3326089A1 (de) * 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
WO1986006959A1 (en) * 1985-05-22 1986-12-04 Liposome Technology, Inc. Liposome inhalation method and system
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
EP0360340A1 (en) * 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
NZ241954A (en) * 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
CA2127877A1 (en) * 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband

Also Published As

Publication number Publication date
KR100391873B1 (ko) 2003-10-17
CN1080114C (zh) 2002-03-06
PT1224929E (pt) 2004-10-29
ES2222306T3 (es) 2005-02-01
CZ288487B6 (en) 2001-06-13
HU217975B (hu) 2000-05-28
AU702898B2 (en) 1999-03-11
NO972660L (no) 1997-06-10
EP0799030B1 (en) 2002-07-24
ATE271382T1 (de) 2004-08-15
IS1848B (is) 2003-02-07
ZA9510753B (en) 1996-06-24
NO972660D0 (no) 1997-06-10
ES2177674T3 (es) 2002-12-16
HUT77648A (hu) 1998-07-28
BR9510422A (pt) 1998-07-07
DK0799030T3 (da) 2002-09-16
CN1171049A (zh) 1998-01-21
DE69533294T2 (de) 2005-05-19
CZ194697A3 (en) 1997-10-15
RU2144819C1 (ru) 2000-01-27
EP0799030A1 (en) 1997-10-08
EP1224929A3 (en) 2002-12-18
EP1224929B1 (en) 2004-07-21
IL116459A0 (en) 1996-03-31
NO315966B1 (no) 2003-11-24
SK81297A3 (en) 1997-11-05
IS4495A (is) 1997-06-03
NZ298168A (en) 1999-08-30
SK283147B6 (sk) 2003-03-04
DE69527542T2 (de) 2003-01-30
DE69527542D1 (de) 2002-08-29
IL116459A (en) 2002-11-10
DK1224929T3 (da) 2004-10-04
TW474823B (en) 2002-02-01
JPH10510828A (ja) 1998-10-20
SA95160484B1 (ar) 2005-10-01
PL183944B1 (pl) 2002-08-30
PT799030E (pt) 2002-11-29
SE9404468D0 (sv) 1994-12-22
DE69533294D1 (de) 2004-08-26
WO1996019207A1 (en) 1996-06-27
EE9700135A (et) 1997-12-15
EP1224929A2 (en) 2002-07-24
EE03381B1 (et) 2001-04-16
MY114211A (en) 2002-08-30
FI972654A (fi) 1997-06-19
MX9704551A (es) 1997-10-31
FI972654A0 (fi) 1997-06-19
US6004574A (en) 1999-12-21
UA44757C2 (uk) 2002-03-15
TR199501632A1 (tr) 1997-03-21
HK1003619A1 (en) 1998-11-06
ATE220900T1 (de) 2002-08-15
AU4359296A (en) 1996-07-10
PL320751A1 (en) 1997-10-27
CA2206803A1 (en) 1996-06-27

Similar Documents

Publication Publication Date Title
AR002261A1 (es) Composicion en polvo para la administracion por inhalacion de polipeptidos utiles en medicina, metodos para la manufactura de dicha composicion, y uso de la composicion para la manufactura de un medicamento para el tratamietno de enfermedades a traves del tracto respiratorio
EE03221B1 (et) Inhaleeritavad ravimpreparaadid, nende valmistamise protsess ja inhalaator nende kasutamiseks
AR002014A1 (es) Formulacion farmaceutica en aerosol, metodo para su manufactura, y metodo para la manufactura de un medicamento para el tratamiento de enfermedades atraves del tracto respiratorio que contienen a dicha formulacion.
NL990012I2 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
MX9700034A (es) Formulacion para la aplicacion por inhalacion.
NO20001087D0 (no) Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
AU644094B2 (en) Medicaments
HK1068606A1 (en) Novel aminobenzoephenones
ATE271852T1 (de) Verbesserte inhalationspräparate
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
ATE295169T1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
MY112888A (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
MY111155A (en) Medicaments
AR014096A1 (es) 17 alfa,8,9-deshidroestradiol y 17 beta delta 8,9 deshidroestradiol, el uso de los mismos para la manufactura de un medicamento, una composicionfarmaceutica que los comprende y un procedimiento para su preparacion.

Legal Events

Date Code Title Description
FG Grant, registration